We would like to draw attention to the case of a female patient with FLT-3 negative secondary acute myeloblastic leukemia (AML) with maturation (cytogenetic report: 46,XX;t(8;21), without additional cytogenetic aberrations). The patient had a 2-year history of myelodysplastic syndrome with multilineage dysplasia (MDS-MLD) treated with azacytidine (75 lg/m 2 sc, d1-5, qd29 with good therapeutic response), and was presented with generalized leukemia cutis (LC) before development of AML with overall disease progression.
The frequency of cutaneous infiltration by neoplastic myeloblasts in leukemia patients has overall incidence between 2 and 20% [1] . The isolated LC diagnosed before any blood or bone marrow evidence of progression of leukemia is very rare. Typically, skin lesions may be localized or generalized and morphologically present as multiple palpable purple nodules, occasionally with central ulceration (Fig. 1a) . Histologically, the myeloblasts are found in the epidermis, dermis or subcutaneous fat tissue with perivascular or periadnexal infiltration (Fig. 1b, c) . The molecular basis responsible for LC suggests a strong association between aneuploidy of chromosome 8, translocation of chromosomes 3, 6, 8, 21 and inversion of chromosome 16 [2] . The skin biopsy with follow-up bone marrow biopsy are essential diagnostic procedures to confirm the diagnosis. Immunophenotyping and immunohistochemistry are useful diagnostic tools in cases in which is difficult to distinguish between the subtypes of leukemia based only on histologic morphology. Finally, the early diagnosis and treatment of LC are crucial factors for improved prognosis and treatment. 
